Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.
Extravascular ICDs were developed to avoid complications such as vascular injuries, lead fractures and lead infections. Although rare, these issues can cause serious, life-threatening complications for patients.
The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.
Cardiology has been shifting from reactionary treatment strategies to a greater emphasis on prevention. This is an especially important trend in heart failure, which is associated with high costs and rising hospitalization rates.
Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
A recent analysis of an already CE-marked, AI-based system that identifies pneumothorax on chest radiographs revealed a weak point in what has largely been considered a reliable support tool.
